Second-Line Therapy for Advanced Colorectal Cancer: EGFR vs. Continuation of VEGF Inhibition

摘要: We review second-line biological therapies for metastatic colorectal cancer (mCRC), including their mechanisms of action, adverse events, survival outcomes, optimal chemotherapy combinations, and sequencing agents. The advent therapeutics targeting vascular endothelial growth factor (VEGF) epidermal receptor (EGFR) pathways has enhanced the benefits afforded by plethora chemotherapeutic agents patients with mCRC over past 10 years, nearly tripling median OS. Individual biomarkers predicting prognosis response to VEGF vs. EGFR therapy have been identified. For who progress on first-line therapy, evidence suggests that continued inhibition may be as efficacious changing less effects. However, after early studies suggest pathway. Biological options progressed concomitant biologic depend individual tumor characteristics choice therapy. Future research should focus prognostic predictive better inform sequential beyond progression.